2 results match your criteria: "Nahariya and Faculty of Medicine in the Galilee Bar-Ilan University Safed[Affiliation]"
The cardioprotective efficacy of TVP1022 against ischemia/reperfusion injury and cardiac remodeling in rats.
Pharmacol Res Perspect
December 2016
Department of Physiology, Biophysics and Systems Biology the Rappaport Faculty of Medicine and Research Institute Technion, Haifa Israel.
Following acute myocardial infarction (MI), early and successful reperfusion is the most effective strategy for reducing infarct size and improving the clinical outcome. However, immediate restoration of blood flow to the ischemic zone results in myocardial damage, defined as "reperfusion-injury". Whereas we previously reported that TVP1022 (the S-isomer of rasagiline, FDA-approved anti-Parkinson drug) decreased infarct size 24 h post ischemia reperfusion (I/R) in rats, in this study we investigated the chronic cardioprotective efficacy of TVP1022 14 days post-I/R.
View Article and Find Full Text PDFSevere Tumor Lysis Syndrome in a Patient With Pancreatic Adenocarcinoma.
Pancreas
April 2016
Galilee Medical Center, Nahariya and Faculty of Medicine in the Galilee Bar-Ilan University Safed, Israel